drugset / Trial / NCT05640778
Neoadjuvant Dalpiciclib Plus Aromatase Inhibitors in Luminal B/HER2-negative Breast Cancer (DANCER)
Phase 2
Unknown
30 enrolled
Second Affiliated Hospital, School of Medicine, Zhejiang University
GeneCast Biotechnology Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
Evaluate the efficacy and safety of Dalpiciclib combined with aromatase inhibitors as a neoadjuvant therapy in Luminal B/HER2-negative breast cancer.
Timeline
- Start
- 2022-10-01
- Primary completion
- 2024-10-31
- Completion
- 2025-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anastrozole | Other / unclassified | — | — |
| Subject | Dalpiciclib | Small molecule | — | — |
| Subject | Letrozole | Other / unclassified | — | — |